Display options
Cite
Bachmann C, Bachmann R, Kraemer B, et al. Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer. Mol Clin Oncol. 2016;5(4):483-487doi: 10.3892/mco.2016.982.
Bachmann, C., Bachmann, R., Kraemer, B., Brucker, S. Y., Staebler, A., Fend, F., Rothmund, R., & Wallwiener, D. (2016). Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer. Molecular and clinical oncology, 5(4), 483-487. https://doi.org/10.3892/mco.2016.982
Bachmann, Cornelia, et al. "Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer." Molecular and clinical oncology vol. 5,4 (2016): 483-487. doi: https://doi.org/10.3892/mco.2016.982
Bachmann C, Bachmann R, Kraemer B, Brucker SY, Staebler A, Fend F, Rothmund R, Wallwiener D. Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer. Mol Clin Oncol. 2016 Oct;5(4):483-487. doi: 10.3892/mco.2016.982. Epub 2016 Aug 05. PMID: 27703680; PMCID: PMC5038892.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2016 Oct;5(4):483-487. doi: 10.3892/mco.2016.982. Epub 2016 Aug 05.

Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer.

Molecular and clinical oncology

Cornelia Bachmann, Robert Bachmann, Bernhard Kraemer, Sara Yvonne Brucker, Anette Staebler, Falko Fend, Ralf Rothmund, Diethelm Wallwiener

Affiliations

  1. Department of Gynecology, University of Tübingen, D-72070 Tübingen, Germany.
  2. Department of General, Visceral and Transplant Surgery, University Hospital of Tübingen, D-72076 Tübingen, Germany.
  3. Department of Pathology, University of Tübingen, D-72076 Tübingen, Germany.

PMID: 27703680 PMCID: PMC5038892 DOI: 10.3892/mco.2016.982

Abstract

The objective of this study was to examine the relevance of pelvic and para-aortic lymph node involvement and the tumour characteristics affecting nodal metastases and survival in primary advanced ovarian cancer. A total of 130 consecutive patients were retrospectively investigated. All the patients received stage-related surgery with pelvic and para-aortic lymphadenectomy. The median follow-up was 53.5 months. The clinicopathological parameters and distribution pattern of nodal metastases were evaluated. Lymph node metastases were detectable in 74.62% of the cases. Overall, both pelvic and para-aortic nodes were affected in 35.9% of the patients, whereas 13.3% had metastases only in the pelvic and 13.3% only in the para-aortic lymph nodes. Histological grade 1/2 and 3, serous and endometrioid histology were independent predictors of nodal metastasis. Serous and endometrioid cancers have shown a predilection for metastasis to the pelvic lymph nodes alone, both to the pelvic and the para-aortic nodes, or the para-aortic nodes alone. Overall survival was significantly positively affected by serous histology with positive nodes (P=0.043). It is crucial to investigate the risk factors and metastatic patterns of such patients in a multicenter analysis to evaluate individual subgroups. Prospective studies are required to investigate the prognostic effect of lymphadenectomy in advanced ovarian cancer and its association with histology and distribution pattern of nodal metastasis.

Keywords: advanced ovarian cancer; histology; lymphadenectomy; nodal involvement; tumour characteristics

References

  1. Int J Gynaecol Obstet. 2014 Jan;124(1):1-5 - PubMed
  2. J Gynecol Oncol. 2013 Jan;24(1):29-36 - PubMed
  3. Cancer. 1998 Oct 15;83(8):1555-60 - PubMed
  4. J Gynecol Oncol. 2013 Oct;24(4):352-8 - PubMed
  5. Cancer. 2009 Mar 15;115(6):1234-44 - PubMed
  6. J Obstet Gynaecol Res. 2010 Oct;36(5):1023-30 - PubMed
  7. Am J Obstet Gynecol. 2006 Dec;195(6):1862-8 - PubMed
  8. J Natl Cancer Inst. 2005 Apr 20;97(8):560-6 - PubMed
  9. Gynecol Oncol. 2007 Jul;106(1):69-74 - PubMed
  10. Int J Gynecol Cancer. 1997 Jan;7(1):18-26 - PubMed
  11. Int J Gynecol Cancer. 2011 Feb;21(2):245-50 - PubMed
  12. Gynecol Oncol. 1997 Jun;65(3):467-72 - PubMed
  13. Gynecol Oncol. 1996 Sep;62(3):360-5 - PubMed
  14. Eur J Gynaecol Oncol. 2009;30(3):289-91 - PubMed
  15. Int J Gynecol Pathol. 2014 May;33(3):302-8 - PubMed
  16. Int J Gynecol Cancer. 2010 May;20(4):520-8 - PubMed
  17. Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1238-44 - PubMed
  18. Int J Gynecol Cancer. 2012 Jul;22(6):987-92 - PubMed
  19. Gynecol Oncol. 2005 Nov;99(2):427-31 - PubMed

Publication Types